Baidu
map

Protein Cell. :寨卡病毒关键药物靶点研究取得进展

2016-05-25 杨海涛等 科学网

近日,由天津大学杨海涛教授领导的科研团队在揭示寨卡病毒关键药物靶点方面取得重要突破,该团队率先解析了寨卡病毒解旋酶1.8埃的晶体结构。解旋酶是设计抗病毒药物的关键靶点,这一高分辨率结构有助于开发治疗寨卡病毒的特效药物。 目前主要依赖于蚊子传播的寨卡病毒正在美洲流行。寨卡病毒感染与新生儿小头畸形以及严重的神经系统综合征密切相关。然而,目前尚无有效的疫苗和抗病毒药物防治该病毒的感染,寨卡



近日,由天津大学杨海涛教授领导的科研团队在揭示寨卡病毒关键药物靶点方面取得重要突破,该团队率先解析了寨卡病毒解旋酶1.8埃的晶体结构。解旋酶是设计抗病毒药物的关键靶点,这一高分辨率结构有助于开发治疗寨卡病毒的特效药物。

目前主要依赖于蚊子传播的寨卡病毒正在美洲流行。寨卡病毒感染与新生儿小头畸形以及严重的神经系统综合征密切相关。然而,目前尚无有效的疫苗和抗病毒药物防治该病毒的感染,寨卡病毒对公共健康仍然是一个严重威胁。科学研究表明,所有病毒似乎都需要一种被称为解旋酶的蛋白质帮助其复制,而寨卡病毒复制过程中,病毒的解旋酶会通过水解三磷酸核苷获取能量,并对双链的RNA进行解链。这一过程是病毒复制的关键步骤之一,因此解旋酶也是寨卡病毒增殖过程中必不可少的蛋白。通过设计针对寨卡病毒解旋酶的小分子抑制剂,有望开发出控制寨卡病毒感染的抗病毒药物。

天津大学的研究团队成功解析了了寨卡病毒解旋酶1.8埃的晶体结构,揭示了该酶在原子分辨率水平的关键特征,这一研究成果以The Crystal Structure of Zika Virus Helicase: Basis for Antiviral Drug Design为题于2016年5月12日在线发表在Protein & Cell杂志上。这一高分辨率药靶的结构解析为科研工作者开发治疗寨卡病毒的临床药物奠定了重要的理论基础。该研究得到国家科技部“973”项目的资助。

英文学术月刊Protein & Cell由高等教育出版社、中国科学院北京生命科学研究院和中国生物物理学会联合创办,自2010年1月起,每月以纸质印刷和在线两种形式出版。报道学科领域包括:生物物理学、细胞生物学、分子生物学、蛋白质学、生物化学、发育生物学、结构生物学、免疫生物学、微生物学、遗传学、神经科学和肿瘤学等,旨在打造一个学术水平高、可读性强、具有全球影响力的生命科学期刊品牌。

Protein & Cell由饶子和院士担任主编,副主编包括中科院北京生命科学研究院院长康乐院士、副院长高福院士、蛋白质科学国家实验室主任许瑞明研究员、牛津大学Bob Sim教授、清华大学胡小玉教授以及中科院生物物理所刘光慧研究员。此外,刊物由60余位该领域国内外知名专家、学者组成编委会,保证稿件的高学术水平和审稿流程的高效、规范、公正。 Protein & Cell关注生命科学和生物医学的前沿热点,文章类型包括研究论文、综述、新闻评论、人物故事等。本刊已被SCI,MEDLINE,BIOSIS, SCOPUS和中国科学引文数据库(CSCD)核心库等收录。

原始出处

Tian H1,2, Ji X3, Yang X1, Xie W1, Yang K4, Chen C1, Wu C1, Chi H1, Mu Z1, Wang Z1, Yang H5,6.The crystal structure of Zika virus helicase: basis for antiviral drug design.Protein Cell. 2016 May 12

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-07-15 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 xugc
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1869393, encodeId=e8a9186939342, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 28 10:15:00 CST 2017, time=2017-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959650, encodeId=25b3195965064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 15 07:15:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360012, encodeId=e4d0136001268, content=<a href='/topic/show?id=6783466083f' target=_blank style='color:#2F92EE;'>#寨卡病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46608, encryptionId=6783466083f, topicName=寨卡病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384930, encodeId=f75f138493071, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512840, encodeId=107f1512840bc, content=<a href='/topic/show?id=f0364660360' target=_blank style='color:#2F92EE;'>#寨卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46603, encryptionId=f0364660360, topicName=寨卡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79610514526, createdName=12498710m14暂无昵称, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601797, encodeId=351b1601e97ba, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605206, encodeId=4368160520672, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri May 27 13:15:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]

相关资讯

Science新闻:美科学家将于2017年开启寨卡疫苗有效性检测临床试验

在华盛顿召开的寨卡病毒风险挑战沟通会议上,来自美国马里兰NIAID的Anthony Fauci表示,在最乐观的情况下,他们将在2018年初对寨卡疫苗的有效性给出答案。 Anthony Fauci表示NIAID计划于今年9月份开始进行实验室制备疫苗的临床检测,准备纳入80人参加研究。如果能够证明该疫苗具备安全性同时可以刺激相关免疫应答,NIAID将于2017年第一季度开启一项2b期研究,用Fa

Cell:寨卡病毒导致小脑症在体外类器官模型中确证

寨卡病毒(Zika virus)疫情出现在研究大脑的新干细胞技术正在完善及进行测试之时。在4月22日的《细胞》(Cell)杂志上,来自约翰霍普金斯大学医学院的研究人员将一种脑区域特异性类器官(organoids)公诸于世,它在三维空间中展示了寨卡病毒影响人类大脑的机制。这些类器官数据支持了寨卡病毒偏好感染神经干细胞,及损伤程度差异取决于感染时间的这些观点。多年来大脑类器官(也叫微型大脑)一直被积极

CRISPR:让寨卡病毒无所遁形

近日,一种快速检测寨卡病毒的试纸诞生,它的出现或许能够降低小头症婴儿的出生率。这种神奇的方法来自CRISPR技术。这个自2013年以来风靡世界的基因编辑技术正在生物医学研究领域引起一场巨变。

加拿大发现首例通过性传播的寨卡病例

加拿大公共卫生部门当地时间4月25日公布实验室检测结果,发现该国首例通过性传播的寨卡病毒病例,该病例出现在安大略省。 当天,加拿大联邦公共卫生局与安大略省公共卫生厅联合发布消息称,从微生物实验室检测到性传播的寨卡病例。官方称该病例为个案。 此前,已有多名加拿大人被发现携带寨卡病毒入境。而此次是首次发现性传播案例。 安大略省的这名患者被怀疑与此前曾经到寨卡病毒流行地区旅行的伴侣有过性接触。

美国将启动寨卡疫苗效力试验

美国将启动寨卡疫苗效力试验 近日,美国国立变态反应与传染病研究所(NIAID)所长Anthony Fauci指出,最乐观的情况是,2018年年初能证明寨卡疫苗的有效性。 Fauci 在一场新闻发布会上称,NIAID计划在80位参与者身上试验其实验室研制的疫苗。如果该疫苗被证明安全,且能够刺激相关免疫响应,NIAID将在2017年第一季度于“高感染风险国家”启动第二阶段研究。相关

研究称欧洲大陆发生寨卡疫情的风险有限

尽管北半球夏季将至,欧洲将面临伊蚊繁殖的活跃期,但法国巴斯德研究所的科研人员针对不同类型伊蚊传播病毒的能力进行的研究显示,目前欧洲大陆出现寨卡疫情的风险仍然有限。 寨卡病毒通常经伊蚊叮咬传播,引发传染性疾病——寨卡热,其症状包括发热、头痛、关节痛、肌肉痛、皮疹等,目前尚无疫苗和有效治疗手段。自去年以来,寨卡病毒在巴西等美洲国家持续肆虐,导致欧洲、北美洲等地区国家也陆续出现零星输入性感染病例

Baidu
map
Baidu
map
Baidu
map